来自MSN20 天
Biogen Wants to Buy Its Partner Sage for Almost No Premium
Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years ...
Yahoo Finance19 天
Biogen CEO sees no burning need for more acquisitions
SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...
Nasdaq1 个月
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...
Reuters23 天
Biogen proposes to buy remaining stake in Sage in $442 million deal
Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...
Seeking Alpha22 天
Sage confirms Biogen’s bid to acquire remaining stake
Sage Therapeutics (NASDAQ:SAGE) has confirmed that the Alzheimer’s drug developer Biogen (NASDAQ:BIIB) has offered to buy all the outstanding shares of common stock that it currently does not ...